Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety, tolerability, and pharmacodynamics of DDP733 for irritable bowel syndrome with constipation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome
• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• DDP733

Snippet

Sponsor: Dynogen Pharmaceuticals | Conditions: Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED